Clinical trials: SARS-COV 2
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
Covid-19, Corona Virus Infection
Phase II RCT to Assess Efficacy of Intravenous Administration of Oxytocin in Patients Affected by COVID-19
Introduction There are currently no treatments with demonstrated efficacy for COVID-19 infection. Epidemiological evidence points to the existence of intrinsic protection factors which make young persons and women more resistant…
- Conditions
- Covid-19, Corona Virus Infection, SARS-CoV 2
- Trial name
- OsCOVID19 (NCT04386447)
- Testing
- Oxytocin, Standard of Care
- Where
- 3 sites in France, Italy
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Coronavirus Infections, SARS-CoV 2
Use of Hydroxychloroquine Alone or Associated for Inpatients With SARS-CoV2 Virus (COVID-19)
The Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV2) has been identified in Wuhan, China, which causes severe pulmonary complications and flu syndrome, which has spread rapidly to all continents.
- Conditions
- Coronavirus Infections, SARS-CoV 2, SARS (Severe Acute Respiratory Syndrome), Pulmonary Disease
- Trial name
- NCT04361461
- Testing
- Hydroxychloroquine Sulfate, Hydroxychloroquine Sulfate + Azythromycin
- Where
- Brazil
- Sponsor
- Apsen Farmaceutica S.A.
SARS CoV 2 Infection, COVID-19
Humoral and Cellular Immunity in First-cycle SARS-CoV-2 Vaccinated COVID-19 Patients
Infection by the recent Coronavirus (SARS-CoV-2) has generated at a pandemic level a new pathology, called COVID-19, characterized by "flu-like" symptoms up to severe acute respiratory failure.
- Trial name
- NCT05338736
- Testing
- LIAISON SARS-CoV-2 TrimericS IgG (DiaSorin), LIAISON SARS-CoV2-IgM (DiaSorin), Human IFN-g ELISpot PLUS (ALP) (AUROGENE)
- Where
- Italy
- Volunteers
- 45 people
- Sponsor
- University Magna Graecia
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
SARS CoV 2 Infection
A Study of EDP-235 in Healthy Subjects
This study is a randomized, double-blind, placebo-controlled study. It will assess the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-235 in healthy adult subjects.
- Trial name
- NCT05246878
- Testing
- EDP-235
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
COVID, SARS-CoV 2
COVID-19 Immune Repertoire Sequencing
This concerns a single-center prospective interventional cohort study. Laboratory-confirmed COVID-19 patients will be asked to donate blood at at least two different timepoints.
- Conditions
- COVID, SARS-CoV 2, Corona Virus Infection, RDT
- Trial name
- IMSEQ (NCT04368143)
- Where
- Belgium
- Volunteers
- 84 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Corona Virus Infection, SARS-CoV 2
Registry for Clinical Presentation and Management of Patients With COVID-19 in the Emergency Room
Patients with COVID-19 usually present in the ED and receive their initial medical check-up here. We will try to gather information of comorbidities and other conditions at the time of presentation of COVID-19 patients to the ED.
- Trial name
- ReCovER (NCT04351854)
- Testing
- Retrospective data collection
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Cologne
Covid-19 Prevention
A Study of Ad26.COV2.S in Adults (COVID-19)
The purpose of the study is to assess the safety, reactogenicity, and immunogenicity of Ad26.COV2.S at 2 dose levels, administered intramuscularly (IM) as a single-dose or 2-dose schedule, with a single booster vaccination…
- Trial name
- NCT04436276
- Testing
- Ad26.COV2.S
- Where
- 12 sites in United States, Belgium
- Volunteers
- 1,085 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
SARS-CoV 2
Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare
The SARS-CoV-2 pandemic and resulting COVID-19 disease causes a substantial burden on healthcare systems. Little is known about how the infection spreads within healthcare.
- Trial name
- NCT04411576
- Testing
- Throat swab sample for measuring current infection with SARS-CoV-2, Blood sample for serology to measure past infection with SARS-CoV-2
- Where
- Sweden
- Volunteers
- 26,326 people
- Sponsor
- Karolinska University Hospital
COVID-19, SARS-CoV 2
Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19
The aim of this possible study is to identify if SARS-CoV-2 can be found in the tear film and conjunctiva of a patient with COVID-19.
- Trial name
- NCT04444596
- Testing
- Conjunctival swab and nasopharyngeal swab
- Where
- Austria
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV 2
Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Context: On March 11, the World Health Organization (WHO) announced the current corona virus disease 2019 (COVID-19) outbreak as a pandemic.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV 2, Coronavirus Infection, Covid19
- Trial name
- NCT04354779
- Testing
- a specifically designed self-administered questionnaire
- Where
- Austria
- Volunteers
- 3,301 people, healthy volunteers welcome
- Sponsor
- AUVA
SARS-CoV 2, COVID-19
Convalescent Plasma for Early Treatment of COVID-19
This is a double-blinded, randomized control trial to assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma as early treatment.
- Trial name
- NCT04390503
- Testing
- Convalescent Plasma (anti-SARS-CoV-2 plasma), Control (albumin 5%)
- Where
- Brazil
- Volunteers
- 223 people, healthy volunteers welcome
- Sponsor
- Andrew Eisenberger
Acute Respiratory Failure, SARS CoV 2 Infection
Bivalirudin Versus Enoxaparin in Critically Ill COVID-19 Patients
Coronavirus Disease (COVID-19) is characterized by a hypercoagulable state, sometimes difficult to be managed with heparin. Bivalirudin, a member of the direct thrombin inhibitor drug class, offers potential advantages compared…
- Conditions
- Acute Respiratory Failure, SARS CoV 2 Infection, Anticoagulants
- Trial name
- NCT05334654
- Testing
- Enoxaparin Sodium, Bivalirudin
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University Magna Graecia
SARS-CoV 2
Exploring Brain Damages After COVID-19 Infection
Although direct evidence is currently lacking, the high identity between SARS-CoV-1 and SARS-CoV-2 suggests, that the latter viral strain could also infect the Central Nervous System (CNS).
- Trial name
- BRAINCOV (NCT04405986)
- Testing
- Auditory Evoked Potentials (AEP), Blink and Masseter Inhibitory Reflex
- Where
- France
- Volunteers
- 38 people
- Sponsor
- University Hospital, Bordeaux
SARS CoV 2 Infection, COVID-19
Diagnosis of Respiratory Viruses in Children With Rhinoswab Junior
A study to investigate Rhinoswab as an alternative method to combined throat and deep nasal (CTDN) swab for respiratory sample collection in children who present to the Royal Children's Hospital (RCH) for viral testing.
- Trial name
- NCT05043623
- Testing
- Rhinoswab Junior, Combined nose and throat swab, Saliva swab
- Where
- Australia
- Volunteers
- 339 people, healthy volunteers welcome
- Sponsor
- Murdoch Childrens Research Institute
Corona Virus Infection, Middle East Respiratory Syndrome (MERS)
Clinical Assessment of Oral Lactoferrin as a Safe Antiviral and Immunoregulatory in Treating COVID-19 Disease
The aim of the study is to clinically use bovine Lf as a safe antiviral adjuvant for treatment and to assess the potential in reducing mortality and morbidity rates in COVID-19 patients.
- Conditions
- Corona Virus Infection, Middle East Respiratory Syndrome (MERS), Acute Respiratory Distress Syndrome, Coronavirus Infection
- Trial name
- COVID-19_LF (NCT04412395)
- Testing
- Lactoferrin (Apolactoferrin)
- Where
- 4 sites in Egypt
- Volunteers
- 516 people
- Sponsor
- National Research Centre, Egypt
SARS-CoV 2, COVID-19
Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19
Study objective is to evaluate the efficacy of the combination of masitinib and isoquercetin in adult hospitalized patients with moderate and severe COVID-19.
- Conditions
- SARS-CoV 2, COVID-19, Coronavirus Disease 2019
- Trial name
- NCT04622865
- Testing
- Masitinib, Isoquercetin, Best Supportive Care
- Where
- 6 sites in France
- Volunteers
- 200 people
- Sponsor
- AB Science
COVID-19, SARS-CoV 2
Carrageenan Nasal Spray for COVID-19 Prophylaxis
The current COVID-19 pandemic is the biggest global healthcare challenge in the last century, and the number of cases in the next 12 months is likely to increase.
- Trial name
- ICE-COVID (NCT04590365)
- Testing
- Carrageenan nasal and throat spray, Saline nasal and throat spray
- Where
- United Kingdom
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Swansea University
Femoral Neck Fractures, SARS-CoV 2
A Study of Outcomes in Patients With Fractured Neck of Femur During the COVID-19 Pandemic
In early 2020 the evolving COVID-19 Pandemic provided the world and medical community with a generational challenge. As a novel disease, countries were left with strategic decisions and many went into social lockdown.
- Trial name
- NCT04375501
- Testing
- Surgery: Dynamic Hip Screw, hemiarthroplasty, hip replacement, intramedullary nail
- Where
- United Kingdom
- Volunteers
- 442 people
- Sponsor
- Barts & The London NHS Trust